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Linking high-risk preventive strategy to 
biomedical-industry market: implications for 
public health1
Ligando a estratégia preventiva de alto-risco ao mercado da 
indústria biomédica: implicações para a saúde pública
Abstract
This paper takes Geoffrey Rose’s concepts on pre-
ventive strategy as the basis for theoretical frame-
work to critically analyse the current approach 
to disease prevention. Rose’s “continuum of risk 
and severity” has widened the scope for preventive 
actions and underpins two approaches: high-risk 
strategy (HRS) and population strategy (PS). Both 
of them produce paradoxes: HRS, despite having a 
good harm-benefit ratio, offers little impact on pub-
lic health; PS has greater impact on public health, 
but offers minimal benefit at individual level. We 
argue that HRS is being misapplied by reducing 
cut-off points for preventive interventions to impact 
morbimortality attributed to specific diseases. This 
tends to medicalize prevention, producing more 
disease related phenomena through screening tech-
niques, and inducing individual affective reactions, 
which require action in the present to secure better 
future health. This context has paved the way for 
speculative preventive medicine, which perceives 
health as a commodity but ignores its implications 
for public health services. 
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nary Prevention; Medicalization; Commodification; 
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Resumo
Este artigo aborda os conceitos de Geoffrey Rose 
sobre estratégia preventiva como base para aná-
lise teórico-crítica da abordagem atual para a 
prevenção de doenças. A proposta de Rose de um 
“continuum de risco e severidade” ampliou as 
possibilidades das ações preventivas ao classificar 
duas abordagens: a estratégia de alto risco (EAR) 
e a estratégia populacional (EP). Ambas produzem 
paradoxos: a EAR, apesar de apresentar boa rela-
ção dano-benefício, oferece pouco impacto para 
a saúde pública; a EP tem maior impacto sobre a 
saúde pública, mas oferece benefícios mínimos 
em nível individual. Argumentamos que a EAR 
tem sido mal utilizada ao reduzir pontos de corte 
para intervenções preventivas para impactar a 
morbimortalidade atribuída a doenças específicas. 
Isso tende a medicalizar a prevenção, produzindo 
mais fenômenos relacionados à doença por meio 
de técnicas de rastreamento, induzindo reações 
afetivas individuais que exigem ação no presente 
para garantir melhor saúde no futuro. Tal contex-
to abre caminho para a prática de uma medicina 
preventiva especulativa, que percebe a saúde como 
mercadoria, mas ignora suas implicações para os 
serviços de saúde pública. 
Palavras-chave: Prevenção de Doenças; Saúde 
Pública; Prevenção Quaternária; Medicalização; 
Mercantilização; Medicina Baseada em Evidências.
Introduction
Evidence-Based Medicine (EBM) has been 
introduced as main paradigm for learning and 
practicing medicine in accordance to the best avail-
able scientific evidence in order to improve qual-
ity standards in clinical care (Harrison; Moran; 
Wood, 2002). In fact, EBM has been a watershed in 
medicine by improving overall quality and safety of 
patients’ clinical care. Furthermore, if applied com-
prehensively, EBM could integrate ‘basic scientific 
principles, the subtleties of clinical judgment, and 
the patient’s clinical and personal idiosyncrasies’ 
(Greenhalgh; Howick; Maskrey, 2014). In addition, 
it has become policymakers’ main instrument for 
assessing effectiveness of biomedical technolo-
gies and treatments. Nevertheless, according to 
Harrison (1998), EBM has also been used as a 
method for rationing healthcare’s finite budget. 
Firstly, it frees politicians from difficult rationing 
decisions by seeming to offer a ‘neutral’ objective 
approach in decision-making processes on current 
and new biomedical technological innovations. 
Secondly, it provides the public with a scientific ex-
planation about policymakers’ rationing decisions. 
Thirdly, its hierarchical framework for assessing 
available medical knowledge has strengthened 
the medical authority (e.g. medical experts and 
researchers) while simultaneously reducing that 
of clinicians. Finally, it allows the production of 
clinical guidelines that doctors are obliged to adopt 
(Harrison; Moran; Wood, 2002). Thus, EBM can also 
be recognized as ‘an indeterminate and malleable 
range of techniques and practices united not by 
particular kinds of methodological rigour, but by 
the pursuit of a new approach to medical knowl-
edge and authority’ (Lambert, 2006, p. 2639). In the 
UK context, this approach has led to the develop-
ment of a robust clinical governance structure that 
paved the way for implementing the largest pay-
for-performance scheme in the world: the Quality 
and Outcomes Framework (QOF) (Norman; Russell; 
Merli, 2016).
Therefore, EBM is not value free and research-
ers’ agendas have been tempered by pharmaceu-
tical industries (Kelly et al., 2015). For example, 
randomized controlled trials (RCT), often regarded 
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as the gold standard of evidence, create distor-
tions arising from one or more of the following: 
manipulation of drug-dose response in both 
study arms (intervention and control); selectively 
enrolling patients most likely to respond to the 
intervention; adopting proxy outcomes; and failing 
to publish negative research findings, which can 
overestimate the benefits of intervention, thereby 
making it harder to replicate their outcomes in 
general population (Greenhalgh; Howick; Maskrey, 
2014). As a result of this criticism, ‘the EBM brand 
has been misappropriated and distorted by vested 
interests’ (Greenhalgh; Howick; Maskrey, 2014, 
p. g3725). In particular, drug and medical devices 
industries increasingly set the research agenda. 
They define what counts as disease and pre-disease 
“risk states”.
This context has fuelled the current debate 
on overdiagnosis and overtreatment, raising 
awareness and concerns about the role of preven-
tive medicine. Overdiagnosis has been defined 
as diagnosis of conditions “that will never cause 
symptoms or death” often as a “consequence of the 
enthusiasm of early diagnosis”. (Malhotra et al., 
2015, p. h2308). These asymptomatic patients have 
been transformed into sick individuals and exposed 
to a range of psychological and physical side-effects 
without the prospect of benefit because they have 
been overtreated (Tesser; Norman, 2016). Thus, an 
increased body of evidence shows that some cur-
rent preventive medicine activities may either lead 
to harm or suggest uncertainties surrounding its 
benefits (Welch; Fisher, 2017). Although prevention 
is portrayed as better than cure, the trend is to exag-
gerate certainty instead of taking a more balanced 
and honest approach to scientific findings and their 
limitations (Rose, 1992).
This article elaborates on Geoffrey Rose’s 
(1992) seminal book, The Strategy of Preventive 
Medicine. We frame the discussion in six sections. 
The first one revisits the definition of disease 
as a ‘quantifiable entity’. Section two presents 
Rose´s approach to prevention: high-risk strategy 
(HRS) and population strategy (PS). Section three 
addresses their embedded paradoxes. In section 
four, we contend that the trends in prevention 
have centred on the misapplication of HRS by 
gradually reducing cut-off points for preventive 
interventions as means for addressing major 
disease outcomes. Based on two examples from 
an ethnographic study (Norman; Russell; Merli, 
2016) of the QOF scheme, our final section high-
lights the advantage of prioritising HRS over PS 
to pharmaceutical industries. We argue that HRS 
has become mainstream in prevention because 
it fits a neoliberal economic approach to viewing 
health as a commodity.
Continuum of risk and severity
The fundamental misunderstanding of Rose’s 
concept of preventive medicine refers to the con-
tinuum of risk and severity. This has helped blur 
the division between normal and pathological 
(Tesser; Norman, 2016). For Rose, the diagnos-
tic criteria with their nosological entities (i.e. 
the international classification of diseases) are 
constructs for decision-making processes which 
doctors traditionally framed as disease diagnosis 
(Rose, 1992). The diagnostic process is, in fact, a 
tool that helps doctors decide whether or not to 
intervene upon the human body, i.e. it sets a clear 
cut-off point for intervention. It falls to profes-
sional judgement to decide whether a phenomenon 
is pathological and, if so, if the pathology warrants 
an intervention.
Rose challenged the limitations of such binary 
thinking and suggested that clinicians should 
think beyond pathological/non-pathological 
dualism, recognising the uncertain character of 
physiological processes. Hence, doctors should 
not just be concerned about whether a patient has, 
or does not have, a disease such as dementia, but 
how much of a disease a person has. Dementia, for 
example, may present across a whole spectrum of 
severity in the population from asymptomatic, 
oligo-symptomatic to frankly manifested. The 
consequences of this line of thought resulted in 
redefining disease as a ‘quantifiable entity’. The 
quantification of disease allowed the expansion 
of medical interventions to individuals within 
the population who would previously have been 
regarded as healthy, since potentially everyone 
has a ‘touch of disease’ (Rose, 1992).
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High-risk strategy and population 
strategy
Rose’s work demonstrates that the normal/patho-
logical divide offers little benefit for population as 
a whole. Moving towards a continuum of risk and 
severity construct, he conceptualised two possible 
preventive medicine strategies: High-Risk Strategy 
(HRS) and Population Strategy (PS). HRS aims to 
separate a problematic minority (or the pathological 
ones) to be targeted through preventive measures 
from the rest of the population considered ‘normal’. 
For instance, patients with underlying Coronary 
Heart Disease (CHD), such as angina, have a high-risk 
cardiovascular profile and should receive statins to 
reduce the likelihood of cardiovascular mortality. In 
contrast, PS aims to influence or to reduce the risk in 
population as a whole through public health initia-
tives. The anti-smoking campaign constitutes a good 
example of PS, where a raft of policy measures such 
as raising public awareness, higher taxation, banning 
smoking in public places and, more recently, in cars 
have had a major impact on tobacco consumption, 
contributing to a marked reduction in tobacco related 
diseases (Pell et al., 2008).
HRS and PS were seen as complementary strate-
gies, but with the latter being more radical and effec-
tive than the former. Rose saw the population as an 
organic whole with changes in its entire distribution 
being more effective in reducing the overall burden 
of disease than targeting individual diseases. The 
PS approach aims to restore or facilitate biologi-
cal homeostasis by creating a safer environment 
through removal of potential sources of ill-health. 
Therefore, changing social context into a healthier, 
fairer and less unequal environment has greater 
impact on human health (Wilkinson; Pickett, 2010). 
Figure 1 shows the left movement of whole risk 
factor distribution in a given population. PS is a 
powerful preventive intervention as it affects not 
only the high-risk, but also moderate to low risk 
individuals in the population.
Figure 1 – Population strategy as powerful preventive option
Rose’s preventive medicine paradox
Preventive medicine strategy is characterised by 
Rose as a double-edged sword and gives rise to the 
preventive paradox both for HRS and PS. The para-
dox of PS is described as ‘a preventive measure that 
brings large benefits to the community offers little 
to each individual participant’ (Rose, 1992, p. 12), 
since each participant possesses low susceptibility 
to disease. For instance, in the case of restriction 
of salt content in processed foods, most of low to 
moderate risk profile individuals will be exposed 
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to this intervention, although individually they are 
unlikely to benefit from it.
Nevertheless, HRS offers globally little impact 
on the population since high-risk groups represent 
a relatively small section of society. Thus, the second 
paradox: ‘the large number of people at a small risk 
may give rise to more cases of disease than the small 
number who are at a high-risk’ (Rose, 2001, p. 431). 
Rose illustrates this paradox with the case of Down’s 
syndrome: 40-years-old or older women carry much 
greater risk profile for having a baby with Down’s 
syndrome, but they contribute only 13% to the total 
burden of the disease. Women who are low risk (below 
30 years of age) produce half of the cases of Down 
syndrome because they form by far the greatest pro-
portion of live births in the population (Rose, 2001).
However, the HRS concept is easily accommo-
dated in medicine because it makes sense to both 
patients and health professionals. Its selective 
character discourages interference with those 
considered as ‘normal’ resulting in positive harm-to-
benefit ratio and improved cost-effectiveness (Rose, 
1992). These factors have contributed to the spread 
of HRS across primary care services.
Solving the paradox: reducing 
the cut-off points for biomedical 
interventions
The low impact of HRS on population health 
should have limited its utility as main preventive 
strategy, but ‘experts’ in public health have solved 
the paradox to which it gives rise by gradually lower-
ing the threshold for intervention in healthy people. 
Figure 2 shows the reduction of a cut-off point for 
defining a preventive intervention. This transforms 
numerous asymptomatic people into sick, requir-
ing more medical interventions and follow-ups. 
Thus, HRS leads inevitably to overdiagnosis and 
overtreatment as most individuals will not benefit 
from medical interventions.
The overemphasis on HRS has the effect of 
embracing more and more moderate to low-risk 
patients, backed by statistical figures, which boost 
the magnitude of the intervention, but distort the 
original ethos of public health (Starfield et al., 
2008). The understanding of diseases as quantifi-
able entities has facilitated researchers to gradu-
ally transform risk factors into diseases (Tesser; 
Norman, 2016) but more importantly, have allowed 
them mathematically reduce the cut-off threshold 
for interventions based on relative risk reduction 
in RCT. This can convey the notion of ‘maximising 
benefit’ for a given intervention despite low baseline 
susceptibility. Table 1 shows that the use of Relative 
Risk Reduction (RRR) numbers overestimates the 
benefit since it continues unchanged (20%) despite 
the decrease in baseline mortality risk or suscepti-
bility (Rembold, 1998). This increases the Number 
Needed to Treat (NNT) which is anchored in absolute 
risk reduction, i.e. the baseline susceptibility.
The expansion of HRS to impact overall popula-
tion outcomes for a specific condition (e.g. statins for 
reducing cardiovascular mortality) predictably in-
cludes more healthy people with moderate to low-risk 
profiles. Thus, the harm-benefit pendulum inevitably 
swings towards the harm end outcome spectrum by 
spreading fear in the population and taking away 
people’s sense of self-security (Heath, 2011).
Rather than applying population measures to ad-
dress macro determinants of health, which can have 
a powerful impact on specific disease morbidity and 
mortality indicators, the default position in health 
promotion has been to individualise and capitalize on 
prevention. This phenomenon has been termed ‘life-
style drift’, namely, ‘the tendency for policy to start 
off recognising the need for action on upstream so-
cial determinants of health inequalities only to drift 
downstream to focus largely on individual lifestyle 
factors’ (Popay; Whitehead; Hunter, 2010, p. 148).
‘Lifestyle drift’ reverses the PS approach, thus 
causing harm to many healthy people in the name 
of a better future population health. In other words, 
public health experts are aiming for population 
effect through targeting the individual, instead of 
acting principally at a ‘whole of society’ and ‘whole-
of-government’ level to impact on the major determi-
nants of health (WHO, 2013). This tension in policy 
arising from the corrosive effects of neoliberalism, 
and its contribution to widening health inequalities 
and poorer health in society, manifests itself in the 
emphasis on individual behavioural change in pref-
erence to tackling social determinants of health.
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Table 1 – Relative Risk Reduction: a powerful number 
for conveying benefit
Mortality Risk  Risk reduction
Control 
(%) 
Treatment 
(%)
Relative 
(%)
Absolute 
(%) 
NNT*
5 4 20 1 100
0.5 0.4 20 0.1 1,000
0.05 0.04 20 0.01 10,000
Source: Rembold, 1998
*NNT Number Needed to Treat.
Policies designed to reduce income disparities 
and confront vested interests of the global corporate 
sector, whose activities contribute to high levels of 
obesity, alcohol misuse and other lifestyle related 
conditions, through tougher regulation and taxa-
tion, are neglected in favour of those which leave 
these structural and commercial interests essential-
ly untouched. Although public health built its repu-
tation on the willingness of many of its key figures, 
like Rudolf Virchow, to challenge the prevailing 
political consensus and power imbalance in society, 
it has in more recent times been reluctant to engage 
with the political determinants of inequalities in 
income, power and resources (Collins; McCartney; 
Figure 2 – High-risk strategy: reducing cut-off points for preventive interventions as a source for overdiagnosis 
and overtreatment
Garnham, 2016). The policy solutions offered are 
therefore failing to target those actors and actions 
responsible for the health gap and widening social 
gradient in health (Marmot, 2015).
Reducing cut-off points in 
timeframe: bringing future into 
present
HRS as a preventive approach pushes health 
staff to apply ‘simulations or probabilistic anticipa-
tions’ about patients’ future health condition based 
on accumulated past statistical and epidemiological 
data (Adams; Murphy; Clarke, 2009). These data 
underpin a range of devices for calculating stan-
dardised individuals’ disease risk profile, which 
requires interventions in the present in order to 
improve their future health profile. Thus, tempo-
ral dimension of care is transformed to produce 
an objectivity that claims truth about patients’ 
fate (Adams; Murphy; Clarke, 2009). This sort of 
speculative preventive medicine ‘must inevitably 
decontextualize and efface the reality of everyday 
life and experience’ (Lock; Nguyen, 2010, p. 26), but 
its figures are rarely discussed.
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individuals’ risk. For instance, a 20% risk predic-
tion implies that over ten years in a cohort of ‘same 
cases’, 20% will have a major cardiovascular event 
such as Myocardial Infarction (MI) or death due to 
cardiovascular disease. Mathematically, patients 
have an 80% chance of not having had an event in 
10 years’ time. This means that most people will be 
alive helping to build a background against which 
the benefits will abound since doctors cannot see the 
population effects by treating individual cases. This 
scenario tends to overestimate the benefit.
Moreover, if taking statins offers a possibility of, 
say, a 40% reduction in cardiovascular disease at the 
population level, this infers that 60% of those tak-
ing statins will still develop Coronary Heart Disease 
(CHD) major events. Finally, amongst individuals 
participating in this preemptive measure, the pro-
tective increment to the baseline is insignificant: 
before intervention the chances of not having a 
CHD event was 80% but after adhering to statins 
for ten years the chances of not having an adverse 
effect due to CHD has only increased to 88%. It 
is undeniable that 8% reduction at a population 
level would represent a big achievement, but the 
means used for reaching these figures need to be 
reassessed. To quote Heath (2010, p. 93): ‘however, 
worthy the end, turning humanity into simply the 
means to achieve it is to undermine what it is to be 
human in a very fundamental way’. Rose’s concept 
that population intervention offers little for each 
individual participant is reinforced and becomes 
even clearer once this is done through an HRS ap-
proach, no matter how much experts play with the 
numbers to ensure statistically significant results 
(Abramson et al., 2013).
High-risk strategy: advantage for 
the pharmaceutical industry
The current preventive strategy adopts ‘techno-
logical fix’ in the hope of giving individual protec-
tion despite the adverse socioeconomic context. 
Rose (1992, p. 48) has pointed out important weak-
nesses of HRS: ‘prevention becomes medicalized’; 
‘success is only palliative and temporary’ which 
means that it needs constant maintenance of ser-
vices by not addressing the diseases’ root cause (i.e. 
All numbers addressed in prevention are an-
chored in population rather than individual level. 
Therefore, health professionals should make this 
clear to their patients by asserting that they aim 
to achieve an effect at population level (at least, 
this is the hope of policymakers). The ‘success’ of 
the intervention depends much more on capitation 
and compliance of patients with similar risk levels 
rather than the treatment of an individual isolated 
case. By adopting HRS as a population intervention, 
it produces uncertainty about who individually will 
benefit from it. For any particular person, treatment 
means that he/she must enrol in what is effectively 
an unbranded ‘clinical trial’ in order to achieve the 
desired population benefit through a sum of indi-
vidualised interventions. The patients are pooled 
in a sea of uncertainty, which is seldom discussed 
in depth with them.
Usually, clinicians have difficulties in predicting 
the effect of a preventive intervention for an indi-
vidual, since population studies have anonymised 
the asymptomatic person in front of them. This 
anonymity cannot be easily overcome by taking a 
patient-centred approach – even using information 
techniques for conveying probability. Additionally, 
clinicians’ misinterpretation of statistics (e.g. use 
of relative risks instead of absolute risk), and, in 
some cases, not balancing against potential harms 
can convey unrealistic benefits of an intervention 
(Malhotra et al., 2015). For instance, clinicians 
often tend to speak to their patients in terms of 
‘Mr “X” your chances are…’, but forget that EBM 
operates at very abstract mathematical realm of 
population-based study trials which know nothing 
about Mr “X”, making it quite impossible in the case 
of preventive measure to transfer results to that 
person in particular. Thus, over time clinicians have 
undergone an acculturation process through train-
ing programmes, whereby this predictive reasoning 
has become normalised as best practice backed by, 
and incentivised to conform to pay-for-performance 
schemes, within which QOF stands as an example 
(Malhotra et al., 2015; Norman; Russell; Merli, 2016).
This predictive reasoning manifests itself 
through templates employed to inform individuals 
of their future cardiovascular outcomes, like the 
QRISK2® template, which automatically predicts 
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socioeconomic health determinants); ‘it is limited 
by poor ability to predict the future of individuals’. 
In other words, HRS creates uncertainties for the 
individuals receiving preventive intervention since 
patients are pooled in a risk-benefit population in-
tervention (discussed further below). Although Rose 
warned of the weakness of HRS, for pharmaceutical 
industries its weakness has become their strength.
Prevention becomes medicalized
The adoption of HRS fosters medicalization of 
preventive activities. This is ‘music to the ears’ of 
drug companies. What has been witnessed during 
the last forty years is a tendency to resignify the us-
age of existing drugs by reducing cut-off points for 
prescribing them and hence labelling more people as 
sick (Lenzer, 2013), as well as by establishing hard-
to-reach targets for cholesterol, diabetes (Hb1Ac), 
blood pressure, obesity and the like (Montori; Isley; 
Guyatt, 2007). This approach has been systemati-
cally applied with the introduction of QOF.
The QOF as a pay-for-performance scheme 
consists of a point-based system that rewards UK 
general practice for achieving certain standards on 
pre-agreed clinical disease criteria. The aim has been 
to improve the quality of clinical care in general prac-
tice by setting an evidence-based clinical governance 
framework. The QOF 2013/2014 contract year offered 
900 points and was organised into four domains: 
Clinical, Public Health, Quality and Productivity, and 
Patient Experience (Norman; Russell; Merli, 2016). 
In some QOF clinical indicators policymakers have 
manipulated cut-off points for intervention and/or 
the range of points achievement of target-disease as 
mean of optimising treatment (Doran et al., 2014). In 
the QOF 2013/2014 contract this strategy was clearly 
used in regard to hypertension: QOF has tightened 
the hypertension target by placing fifty points (i.e. 
more money) to a ‘newly’ introduced QOF hyperten-
sion indicator HYP003 (requiring the blood pressure 
to be below 140/90) against ten points for HYP002 
(requiring blood pressure to be below 150/90 – Table 
2). This led to the inclusion of more patients under a 
tight blood pressure control.
By incentivizing reduced cut-off points, the QOF 
significantly increases the number of target people 
needing medical intervention, since it works at the 
population level or practices’ catchment area. This 
process increases the number of laboratory tests, 
follow ups, and drugs being prescribed to reach 
a lower blood pressure threshold target within a 
cohort of hypertensive patients.
The QOF indicators for diabetes are another 
example of how policymakers have played with cut-
off points and the upper-end threshold of a disease 
management quality standard. One of the criteria 
for a good diabetes control is through monitoring 
the level of haemoglobin A1c (HbA1c). Table 3 illus-
trates the fluctuation in HbA1c targeting and the 
increase in quality standards by expanding the up-
per range for maximum points. This leads to more 
patients on tighter diabetes control regimens and 
increase in medication usage.
Table 2 – QOF hypertension indicator targets, points and range of achievement, 2013/2014
Hypertension (HYP) indicators Points
Achievement 
thresholds
Records
HYP001. The contractor establishes and maintains a register of patients with established 
hypertension.
6 44 – 84%
Ongoing Management
HYP002. The percentage of patients with hypertension in whom the last blood pressure reading 
(measured in the preceding nine months) is 150/90 mmHg or less.
10 40 – 80%
HYP003. The percentage of patients aged 79 or under with hypertension in whom the last blood 
pressure reading (measured in the preceding nine months) is 140/90 mmHg or less (NICE 2012 menu 
ID: NM53).
50 40 – 80%
Source: United Kingdom, 2013.
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Table 3 – Diabetes level of HbA1c in the previous fifteen months* organised by points’ allocation (P), range of 
achievement (R), and QOF contract year
QOF year 2004/2005 2006/2007 2009/2010 2011/2012 2013/2014
HbA1c target 
mmol/mol (%)
P R (%) P R (%) P R (%) P R (%) P R (%)
≤53 / (7.0) 17 40 – 50
≤59 / (7.5) 16 25 – 50 17 40 – 50 - - 17 40 – 50 17 35 – 75
≤64 / (8.0) - - - - 8 40 – 70 8 40 – 70 8 43 – 83
≤75 / (9.0) - - - - 10 40 – 90 10 40 – 90 10 52 – 92
≤86 / (10.0) 11 25 -85 11 40 – 90 -
Source: Norman, 2015
* QOF 2013/14 reduced the length to reach the target to 12 months.
Table 3 shows that in 2009/2010 QOF introduced 
three tiers for HbA1c levels, placing more points 
on lower cut-off points (≤53/7.0%=17 points) induc-
ing practitioners to be more aggressive in treating 
their diabetic patients. In 2013/2014 QOF contract 
year expanded the upper limits in all three tiers. 
Once more policy-makers have allocated more QOF 
points to lower bands of HbA1c: 17 QOF points to 
HbA1c ≤59 mmol/mol and eight QOF points to HbA1c 
≤64 mmol/mol. This meant that most diabetic pa-
tients had their levels of HbA1c geared towards the 
bottom end of HbA1c range, potentially increasing 
the use of medication and side effects (e.g. hypo-
glycaemia with hospitalisation). Nonetheless, the 
benefit of such intervention remains controversial 
as diabetes tight control (HbA1c below 6%) in-
creases patients’ mortality rate (Currie et al., 2010). 
Ironically, during the last decade, the UK has expe-
rienced a 60% rise in diabetes cases, accounting for 
‘10% of the NHS drugs bill’ as ‘nearly £869m was 
spent on drugs, including insulin and metformin, 
marking a sharp rise from the £514m being spent a 
decade ago’ (Gallagher, 2015).
The adoption of HRS inevitably increases the 
consumption of biotechnologies and drugs (expand-
ing the use of existing drugs which do not require 
further research cost for the pharmaceutical indus-
try), but simultaneously drains public health re-
sources. Most QOF domains focus on individualised 
preventive actions via consumption of biotechnolo-
gies and drugs. Polypharmacy has become the norm 
since the introduction of QOF: from 2004 to 2011 
‘prescriptions for statins doubled, for angiotensin 
converting enzyme inhibitors (for blood pressure 
control) and diabetic drugs nearly doubled, for anti-
depressants rose 60%, and for steroid inhalers rose 
30%’ (Spence, 2013, p. f1498). Despite this increase 
in medication usage, cardiovascular mortality has 
not diminished during the QOF’s ten years of exis-
tence (Kontopantelis et al., 2015).
Success is only palliative and temporary
HRS is considered a palliative rather than a radi-
cal strategy as it does not address the underlining 
problems of disease causation. Thus, when imple-
mented it requires constant maintenance. Looked 
at closely, HRS implies screening the population, 
which is a sieving process whereby asymptomatic 
people will be classified and targeted for preventive 
intervention. This process inevitably produces a 
snowball effect by generating new entities: posi-
tive results, pseudo-positive results (the source of 
overdiagnosis), false-positives, false-negatives, 
and borderline diseases (e.g. glucose intolerance, 
subclinical hyperthyroidism, cervical intraepithe-
lial neoplasia [CIN, 1,2,3] etc.) multiplying health 
activities (and consequently the costs) in the name 
of optimising health (Raffle; Gray, 2007). This again 
creates a market reserve to be exploited by the bio-
techno-industrial complex operating upon a land-
scape made up of the collective human body. The 
strategy of this industrial complex may involve in-
creasing patients’ awareness about disease-related 
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risks and specific preventive measures to be con-
sumed, as well as by improving doctor-patient ef-
fective ‘therapeutic’ alliances through powerful dis-
courses of EBM (Lambert, 2006) distilled into a set 
of financially incentivized scientific-bureaucratic 
rules (Harrison; Moran; Wood, 2002) embedded in 
pay-for-performance schemes to which clinicians 
have to conform (Norman; Russell; Merli, 2016).
Poor ability to predict individuals’ future 
HRS lacks predictive power upon individuals’ 
future health. The current preventive medical 
model derives from individuals’ uncertainty about 
the benefit of medical interventions. Based on 
large population studies or their meta-analyses, 
the model assumes that what holds for the sample 
(population trial) also holds for the whole popula-
tion (inductive probabilistic/empiricist reasoning) 
just because individuals carry some biometrical re-
semblance (Harrison, 1998; Whitehead, 1967). This 
reinforces the concept of a socioeconomic decon-
textualized, collective and universal body that can 
be standardised for biomedical interventions (Lock; 
Nguyen, 2010). However, individual patients (and 
their doctors alike) tend to have a realist, determin-
istic reasoning tradition (Harrison, 1998) because 
they experience in their bodies the interventions 
and effects of medical practice.
The probabilistic reason based on empirical 
studies generates fetishized numerical concepts 
such as the NNT: the number of people needed to 
receive the intervention, during a certain period of 
time (five or ten years) to prevent one event (e.g. mor-
tality due to myocardial infarction). Suppose that 
the NNT is 100, meaning that 100 people should be 
treated during ten years to prevent one MI. From the 
patient’s perspective, he/she believes they are the 
chosen one amongst 100, because each of them expe-
riences the effects of preemptive medical treatment 
(deterministic/realistic reasoning). This context of 
indeterminacy helps create the paradox of popular-
ity: ‘the greater overdiagnosis and overtreatment, 
the more people there are who believe they owe their 
health or even their lives’ (Raffle; Gray, 2007, p. 68) 
to medical interventions, contributing to strength-
ening medicalization process.
Table 1 illustrates that the inclusion of moderate 
to low-risk increases NNT, amplifying harms due 
to reduced prospects of benefit, while expanding 
the market for ‘preventive’ medications. Take for 
example NICE guidelines (United Kingdom, 2014) 
for lipid disorders: if the person being assessed 
by QRISK2® calculator has a 10% or greater risk of 
having a cardiovascular event, like one MI in ten 
years, clinicians are authorised to offer statin as a 
preventive measure. This group of people has been 
converted into a ‘high-risk’ group purely through 
population health modelling (Bauer, 2013) configur-
ing an example of primary prevention, since they do 
not have clinically established CHD.
The proliferation of risk device predictors (i.e. 
clinical decision-support software, or web-based 
self-tests) within which individuals have to adjust 
themselves ‘to routinized likelihoods, hedged 
bets and probable outcomes’, have strengthened a 
speculative preventive model of practicing medicine 
(Adams; Murphy; Clarke, 2009, p. 247). Several elec-
tronic templates are employed to inform individuals 
of their future adverse outcomes. These include 
cardiovascular risk assessment (QRISK2® tem-
plate), the 10-year prediction of absolute fracture 
risk (FRAX2 template) or even the use of isolated 
biomarkers such as HbA1c to predict micro-vascular 
complications. In the UK, general practice can 
use three different CVD risk-assessment scores 
(Framingham, Joint British Society 2 (JBS2), and 
QRISK®2). Nevertheless, the two first devices are 
known to overestimate the risk ‘by up to fifty per 
cent in most contemporary northern European 
populations, particularly for people living in more 
affluent areas and underestimate risk in higher 
risk populations, such as people who are the most 
socially deprived’ (United Kingdom, 2013, p. 156). 
Thus, despite the aspiration of precise and individu-
alised type of preventive medicine, reality shows 
otherwise, since these forecasting tools vary in their 
external validity (Bayer; Galea, 2015).
The prospect of extending a preventive individu-
alised intervention to those with low to moderate 
risk has turned this type of preventive measure 
questionable, regardless of how the numbers are 
constructed to create sound ‘evidence’ (Abramson 
et al., 2013). In market economy, the high-risk 
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strategy to disease prevention has been adopted, 
because it also produces ‘certain economic profit, 
a certain political utility […] supported by global 
mechanisms and, finally, by the entire system of 
the State’ (Foucault, 2003, p. 33). In this context, 
the state has become the animator of the biomedi-
cal sector economy by strengthening the market 
of biomedical technologies and pharmaceutical 
industries (Rose, 2006).
Final Remarks
This article has critically analysed what Geoffrey 
Rose refers to as ‘additive’ preventive activities via 
high-risk strategy, i.e., the prescription of artificial 
substances (usually a drug) to an individual patient 
to prevent unwanted outcomes. Nevertheless, HRS 
can be safely used when reducing individual’s ex-
posure to potential health hazards, i.e. restoring 
body’s ‘normal’ physiological condition as in the 
reduction of tobacco and excessive alcohol con-
sumption, processed food intake and food pesticide 
usage, and sedentarism. These lifestyle measures 
‘can be presumed to be generally safe, and they can 
therefore be accepted on the basis of a reasonable 
presumption of benefit’ (Rose, 1992, p. 94). They 
are also theoretically consistent and validated by 
the available evidence and scientific knowledge. 
However, we understand that policymakers should 
concentrate efforts in population risk/mortality 
burden intervention policies to improve health more 
generally rather than focusing on ‘the overestima-
tions of the utility of individual risk factors in 
causing ill health in populations’ (Starfield et al., 
2008, p. 583).
Finally, awareness of sophisticated biases and 
vested interests in biomedical research is build-
ing momentum within the scientific community. 
The Choosing Wisely movement (Malhotra et al., 
2015) and the recent “The Evidence-Based Medicine 
Manifesto for Better Healthcare” are setting an 
agenda for a real EBM that favours a more compre-
hensive and holistic view of clinician-patient rela-
tionship and reduction of ‘questionable research 
practices, bias, and conflicts of interests’ (Heneghan 
et al., 2017). By shedding light on the misapplication 
of HRS as a mainstream preventive approach to 
the masses we echo and reaffirm the same voices. 
The introduction of a technological fix via HRS to 
tackle the burden of disease in a population is a 
primary source of overdiagnosis, and consequently 
overtreatment, since most healthy people who are 
being labelled and treated will not succumb to the 
fateful outcome awaiting them. This medicaliza-
tion process is morally and technically unjustified 
(Heath, 2010) and the public and health profession-
als need to be aware of the underlying issues which 
have led to this state of affairs.
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